Teva announced that the FDA has approved ProAir HFA (albuterol sulfate inhalation aerosol) with a dose counter for use in patients >4 years of age for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm (EIB). The dose counter is designed to help these patients, as well as their caregivers, keep track of the number of doses remaining in the canister. The new product will be commercially available later this year.

ProAir HFA, a short-acting β2-agonist, works to relax the smooth muscle of all airways, from the trachea to the terminal bronchioles.

For more information call (888) 838-2872 or visit